Background: Evidence on effectiveness and safety of methotrexate (MTX) in pediatric psoriasis is scarce. Background: Evidence on effectiveness and safety of methotrexate (MTX) in pediatric psoriasis is scarce. Objectives: To study the effectiveness and safety of MTX in pediatric plaque-type psoriasis and its influence on quality of life (Qol) in daily clinical practice. BACKGROUND: Evidence on effectiveness and safety of methotrexate (MTX) in pediatric psoriasis is scarce. OBJECTIVES: To study the effectiveness and safety of MTX in pediatric plaque-type psoriasis and its influence on quality of life (Qol) in daily clinical practice. Medical and scientific articles about Psoriasis, written by M Seyger. 5 Review Efficacy and safety of treatments for childhood psoriasis: a systematic literature review. 9 Clinical Trial Good clinical response to anti-psoriatic treatment with adalimumab and methotrexate does not inflict a direct effect on compartmentalization of T-cell subsets: a pilot study. 12, Article, Systemic treatments in paediatric psoriasis: a systematic evidence-based update.
Background: Strategies for transitioning patients with psoriasis from suboptimal therapy have not been delineated. Objective: We sought to determine the efficacy and safety of transitioning to adalimumab for the treatment of psoriasis in patients with suboptimal response to prior therapy with etanercept, methotrexate (MTX), or narrowband (NB)-ultraviolet (UV)B phototherapy. Conclusion: Propranolol appears to be an effective and well-tolerated treatment for ulcerated IH. More evidence-based studies on psoriasis subjects are needed to explore the practical application of subcutaneous methotrexate as a treatment option for severe recalcitrant psoriasis. Background: Although oral methotrexate is an effective first-line traditional systemic therapy for psoriasis, the use of the subcutaneous form of methotrexate for the treatment of psoriasis has not been fully established. In gathering information regarding SC MTX’s safety and tolerability profile, we examined the data for its safety profile in RA patients, since the dosages used to treat the majority of RA and psoriasis patients are similar. However, there continues to be a scarcity of studies directly examining SC MTX for the management of psoriasis. Phototherapy and systemic therapy with methotrexate, acitretin and cyclosporin have limited use because of lower tolerability in children and cumulative toxicities.
Abstract Background: The Psoriasis Area and Severity Index (PASI) is not able to measure small affected areas in a body region which is important for assessing the performance of high-effective treatment. Systemic treatments in paediatric psoriasis: a systematic evidence-based update. Review the data evaluating the safety and effectiveness of switching to CT-P13 accumulated thus far from clinical studies and real-world experience. Despite the scarce evidence, MTX has become the mainstay of treatment for JIA-associated uveitis 19.
An exacerbation of uveitis during etanercept therapy occurred in only one child (7). Isotretinoin is a remarkably effective drug for severe, recalcitrant acne vulgaris. However, there are limited evidence-based reviews on their efficacy, short-term safety, and tolerability. This review presents the reader with an overview of the current understanding of the pathophysiology, diagnosis, and treatment of pediatric psoriasis, with an emphasis on the available data in the literature that pertains to the use in children of currently available topical and systemic therapies, including topical corticosteroids, vitamin D analogs, phototherapy, systemic immunosuppressive medications, and biologic agents. Methotrexate (MTX) is an effective treatment for psoriasis but its use is limited by its toxicity.